Replies to post #133 on TScan Therapeutics Inc (TCRX)

[crazy horse 0]

A Buyout is not out of the Question

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

On another topic, it appears that Amgen Oncology does not currently have a TCR-T Modality category in their pipeline.

see here:

https://www.amgenoncology.com/clinical-trial-finder.html#modality

then click on Oncolytic Immunotherapy

https://www.amgenoncology.com/modalities/oncolyticimmunotherapy.html

Physicians have long observed that certain viruses can slow the progression of cancer. Oncolytic immunotherapy aims to harness this potential by using genetically modified viruses to target tumors in several important and complementary ways.1

By deleting certain genes, viruses can be reprogrammed to replicate in tumor cells but not in normal cells. This selective viral replication causes the tumor cells to lyse—releasing tumor-specific antigens.1 The virus can also be modified to produce human GM-CSF, signaling dendritic cells to the site of the lysed tumors where they encounter tumor antigens—generating a broad immunotherapeutic response that can help cytotoxic T cells to recognize and attack distant metastases throughout the body.

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

Click on Technology https://www.tscan.com/